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Abstract This study was conducted by the Japanese
Society of Chemotherapy and is the ﬁrst nationwide study
on bacterial pathogens isolated from patients with urinary
tract infections at 28 hospitals throughout Japan between
January 2008 and June 2008. A total of 688 bacterial
strains were isolated from adult patients with urinary tract
infections. The strains investigated in this study are as
follows: Enterococcus faecalis (n = 140), Escherichia
coli (n = 255), Klebsiella pneumoniae (n = 93), Proteus
mirabilis (n = 42), Serratia marcescens (n = 44), and
Pseudomonas aeruginosa (n = 114). The minimum
inhibitory concentrations of 39 antibacterial agents used
for these strains were determined according to the Clinical
and Laboratory Standards Institute (CLSI) manual. All
Enterococcus faecalis strains were susceptible to ampi-
cillin and vancomycin. Although a majority of the
E. faecalis strains were susceptible to linezolid, 11 strains
(7.8%) were found to be intermediately resistant.
The proportions of ﬂuoroquinolone-resistant Enterococ-
cus faecalis, Escherichia coli, Proteus mirabilis, and
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S. marcescens strains were 35.7%, 29.3%, 18.3%, and
15.2%, respectively. The proportions of E. coli, P. mira-
bilis, K. pneumoniae, and S. marcescens strains producing
extended-spectrum b-lactamase were 5.1%, 11.9%, 0%,
and 0%, respectively. The proportions of Pseudomonas
aeruginosa strains resistant to carbapenems, aminoglyco-
sides, and ﬂuoroquinolones were 9.2%, 4.4%, and 34.8%,
respectively, and among them, 2 strains (1.8%) were
found to be multidrug resistant. These data present
important information for the proper treatment of urinary
tract infections and will serve as a useful reference for
periodic surveillance studies in the future.
Keywords Surveillance  Drug susceptibility  Urinary
tract infection
Introduction
Urinary tract infections are among the most common dis-
eases caused by bacteria in adults and should be treated
with effective antibiotic chemotherapy. In fact, more than 8
million patients with urinary tract infections visit urology
or gynecology clinics per year in the United States [1]. The
treatment of urinary tract infections is becoming more
difﬁcult because of increasing resistance to antibiotics.
To investigate the occurrence of uropathogenic bacteria
and their antimicrobial susceptibility, the Japanese Society
of Chemotherapy (JSC) collected information from across
the nation between January 2008 and June 2008. Bacterial
strains were delivered to the Central Surveillance Labora-
tory with the cooperation of 28 hospitals throughout Japan.
Conﬁrmation of bacterial species and antibiotic suscepti-
bility tests were consolidated at the Central Surveillance
Laboratory to minimize potential technical differences
among local laboratories. This study was limited to
Enterococcus faecalis, Escherichia coli, Klebsiella pneu-
moniae, Proteus mirabilis, Serratia marcescens, and
Pseudomonas aeruginosa because these organisms are the
major causal agents of urinary tract infections.
This study shows the susceptibility of the 688 strains of
urinary tract pathogens listed above to 39 antibacterial
agents. Data were analyzed for the incidence of resistant
strains, extended-spectrum b-lactamase (ESBL)-producing
strain, multidrug-resistant P. aeruginosa (MDRP), and van-
comycin-resistant enterococci (VRE). The results obtained
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from this study can be used as a reference for future studies
by the JSC and other organizations as well.
Materials and methods
Strains and quality control
Reference strains used were E. faecalis ATCC29212,
E. coli ATCC25922, E. coli ATCC35218, and P. aeru-
ginosa ATCC27853. Clinical strains were collected as
follows. The causal agents of urinary tract infection [2]
were isolated from self-voided urine of adult patients with
underlying or preexisting diseases at the 28 hospitals listed
in Table 1 and were delivered to the Central Surveillance
Laboratory. The criteria for a diagnosis of urinary tract
infection were (a) bacterial count of 105 colony-forming
units (cfu)/ml or more and (b) 10 or more white blood cells/
high-power ﬁeld (hpf) in the midstream urine sample [2].
The following symptoms were also considered as clinical
criteria for urinary tract infections: underlying disease,
fever, micturition pain, pollakiuria, residual sensation,
urgency, voiding disorders, lower abdominal disorders,
lower abdominal pain, and lumbar pain. Bacteria deﬁned as
uropathogens met the aforementioned criteria and poten-
tially caused uropathogenicity.
The bacterial species were primarily identiﬁed at the
local laboratory, suspended in preservation broth in Micro-
bank tubes (Asuka Junyaku, Tokyo, Japan) at -208C, and
delivered to the Central Laboratory, Research Center for
Anti-infective Drugs of Kitasato University. The patient’s
clinical data and the bacterial species identiﬁed were
recorded on a standardized data sheet. The microbiological
data obtained were analyzed according to the clinical set-
tings and proﬁles of the patients.
A total of 715 strains were delivered to the Central
Laboratory and were stored at -808C for future investi-
gation. Six hundred and eighty-eight strains were investi-
gated in this study: Enterococcus faecalis (140),
Escherichia coli (255), Klebsiella pneumoniae (93), Pro-
teus mirabilis (42), Serratia marcescens (44), and Pseu-
domonas aeruginosa (114).
Determination of minimum inhibitory concentration
(MIC) of antibiotics
The MIC of an antibiotic was determined by the micro-
broth dilution method according to CLSI standards M7-A7
[3] using a MIC2000 System (Eiken Chemical, Tokyo,
Japan). In brief, Mueller–Hinton broth with an adjusted
cation concentration (Ca2? 25 mg/l, Mg2? 12.5 mg/l; CA-
MH broth) was used throughout. Bacterial cells were
grown overnight, and the ﬁnal bacterial suspension was
adjusted to 5 9 104 cfu/well (5 9 105 cfu/ml) and incu-
bated at 358 ± 28C for 16–20 h. Antibiotic susceptibility
of the bacterium was categorized into three classes,
namely, susceptible, intermediate, or resistant, according to
the MIC breakpoints recommended by CLSI standards
M100-S18 [4]. The MIC interpretive standard was adopted
from the CLSI recommendation using the following ref-
erence strains: E. faecalis ATCC29212 for Enterococcus
faecalis; E. coli ATCC25922 for Escherichia coli, Serratia
marcescens, Klebsiella pneumoniae, and Proteus mirabilis;
P. aeruginosa ATCC27853 and E. coli ATCC25922 for
Pseudomonas aeruginosa. E. coli ATCC35218 was also
used for the MIC determination of b-lactam antibiotics in
the presence of b-lactamase inhibitors in these strains
except E. faecalis.
Table 1 Cooperative medical institutions in Japan
Fujita Health University, Toyoake, Aichi
Fukuoka Shin Mizumaki Hospital, Mizumaki, Fukuoka
Gifu Prefectural General Medical Center, Gifu, Gifu
Gifu University Hospital, Gifu, Gifu
Hokkaido Social Insurance Hospital, Sapporo, Hokkaido
Hyogo College of Medicine, Nishinomiya, Hyogo
Ikei Hospital, Kobayashi, Miyazaki
Japanese Red Cross Kobe Hospital, Kobe, Hyogo
Japanese Red Cross Okayama Hospital, Okayama, Okayama
Japanese Red Cross Shizuoka Hospital, Shizuoka, Shizuoka
Jikei University Afﬁliated Aoto Hospital, Katsushika, Tokyo
Kagoshima University Hospital, Kagoshima, Kagoshima
Kizawa Memorial Hospital, Minokamo, Gifu
Kobe University Hospital, Kobe, Hyogo
Minami Seikyou General Hospital, Nagoya, Aichi
Munakata Suikokai General Hospital, Fukutsu, Fukuoka
Muroran City General Hospital, Muroran, Hokkaido
National Hospital Organization Kagoshima Medical Center,
Kagoshima, Kagoshima
National Hospital Organization Okayama Medical Center,
Okayama, Okayama
Nippon Steel Hirohata Hospital, Himeji, Hyogo
Nishi Kobe Medical Center, Kobe, Hyogo
Ogaki Municipal Hospital, Ogaki, Gifu
Okayama Citizens’ Hospital, Okayama, Okayama
Okayama University Hospital, Okayama, Okayama
Saiseikai Sendai Hospital, Satsumasenndai, Kagoshima
University of Miyazaki Hospital, Kiyotake, Mityazaki
University of Occupational and Environmental Health, Kitakyushu,
Fukuoka
Yakumo General Hospital, Yakumo, Hokkaido
Listed in alphabetical order; locations by city and prefecture
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Antibacterial agents
The antibiotic-impregnated microplates were purchased
from Eiken Chemical. The following antimicrobial agents
were used, abbreviated as indicated in parentheses: ampi-
cillin (ABPC), piperacillin (PIPC), clavulanic acid-amoxi-
cillin (CVA/AMPC), sulbactam-ABPC (SBT/ABPC),
tazobactam-PIPC (TAZ/PIPC), cefaclor (CCL), cefditoren
(CDTR), cefcapene (CFPN), cefazolin (CEZ), cefotiam
(CTM), ceftriaxone (CTRX), ceftazidime (CAZ), cefpirome
(CPR), cefepime (CFPM), cefmetazole (CMZ), ﬂomoxef
(FMOX), imipenem (IPM), panipenem (PAPM), merope-
nem (MEPM), biapenem (BIPM), doripenem (DRPM),
faropenem (FRPM), aztreonam (AZT), gentamicin (GM),
isepamicin (ISP), amikacin (AMK), ciproﬂoxacin (CPFX),
levoﬂoxacin (LVFX), tosuﬂoxacin (TFLX), gatiﬂoxacin
(GFLX), pruliﬂoxacin (PUFX), pazuﬂoxacin (PZFX), min-
ocycline (MINO), vancomycin (VCM), linezolid (LZD),
colistin (CL), polymyxin-B (PL-B), fosfomycin (FOM), and
sulfamethoxazole-trimethoprim (ST).
Detection of b-lactamase production
To detect b-lactamase production in gram-negative bacte-
ria, a Nitroceﬁn disk (Ceﬁnase; BD, Japan) was used
according to the reference manual supplied by the manu-
facturer. The Cica-Beta Test (Kanto Chemical, Tokyo,
Japan), a recently developed rapid method, was used to
detect ESBL and metallo-b-lactamase (MBL)-producing
gram-negative bacteria by directly scraping the colony and
applying it on the disk [5, 6].
Results
Background of patients
A total of 688 bacterial strains isolated from patients
diagnosed with urinary tract infections complicating
underlying diseases were studied. The clinical settings,
proﬁles, and background of the patients are shown in
Table 2. Among them, 216 patients were hospitalized
(31.4%) with preexisting diseases at the time of the study.
The following bacterial species were isolated from the
hospitalized patients: Enterococcus faecalis, 36.4% (51/
140), Escherichia coli, 22.0% (56/255), Klebsiella pneu-
moniae, 34.4% (32/93), Proteus mirabilis, 23.8% (10/42),
Serratia marcescens, 29.5% (13/44), and Pseudomonas
aeruginosa, 47.4% (54/114). The MIC of the 39 antibiotics
on these isolates and their spectrum of effective antibiotics
are summarized in Table 3.
Antimicrobial susceptibility of the Enterococcus
faecalis strains
TheMIC90 of penicillin derivatives in 140 strains ofE. faecalis
was 4 lg/ml (Table 3). The MIC90 of cefpirome, a fourth-
generation cephalosporin, in E. faecalis appeared to be
64 lg/ml. Carbapenems showed excellent antimicrobial
activity with MIC90 of 2–8 lg/ml. The MIC90 of ﬂuoroquino-
lones inE. faecaliswas 32–128 lg/ml, and 35.7%of the strains
were ﬂuoroquinolone resistant (Fig. 1). The MIC cumulative
curves of ﬂuoroquinolones showed two peaks, at *0.25–2
lg/ml and *32–128 lg/ml, and the MIC difference among
six ﬂuoroquinolones was roughly fourfold (Fig. 2). All the
E. faecalis were vancomycin susceptible so far, and 11 strains
(7.9%) were found to be intermediately resistant to linezolid.
Antimicrobial susceptibility of the Escherichia coli
strains
Escherichia coli comprised the largest number (255 of 688;
37.1%) of isolates in the study. The MIC90 of two penicillin
Table 2 Background of patients
Total 688
Inpatients 216 (31.4%)
Outpatients 472 (68.6%)
Male 345 (50.1%)
Female 341 (49.6%)
Unknown 2 (0.3%)
Age (years)
20–29 14 (2.0%)
30–39 15 (2.2%)
40–49 19 (2.8%)
50–59 70 (10.2%)
60–69 129 (18.8%)
70–79 236 (34.3%)
80– 205 (29.8%)
Underlying disease
Neurogenic bladder 346 (50.3%)
Prostatomegaly 120 (17.4%)
Bladder cancer 83 (12.1%)
Hydronephrosis 37 (5.4%)
Nephrolithiasis 34 (4.9%)
Prostate cancer 33 (4.8%)
Ureterolithiasis 24 (3.5%)
Ureterostenosis 21 (3.1%)
Cystolithiasis 17 (2.5%)
Vesical diverticulum 7 (1.0%)
Vesicoureteral reﬂux 7 (1.0%)
Nephrocystosis 5 (0.7%)
Other 130 (18.9%)
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derivatives (ABPC and PIPC) in these E. coli strains was
C256 lg/ml, whereas the MIC90 of penicillin derivatives in
the presence of the b-lactamase inhibitors (CVA/AMPC,
SBT/ABPC, and TAZ/PIPC) was decreased to 4–32 lg/ml
(Table 3; Figs. 3, 4). The MIC90 of three oral cephalo-
sporins, six parenteral cephalosporins, one cephamycin,
and one oxacephem was 0.125–32 lg/ml, and, therefore,
most of them were active against E. coli, except for two
cephalosporins (CCL and CEZ) (see Table 3; Fig. 5). The
carbapenems showed the highest activity among all the
antibiotics tested against E. coli, with MIC90 of
B0.06–0.25 lg/ml. Thirteen ESBL-producing strains (13/255;
5.1%) were detected. The MIC90 of six ﬂuoroquinolones in
these E. coli strains was 8 to C32 lg/ml, and the ratio of
resistant strains was about 30%. TheMIC cumulative curves
showed two peaks, at *0.125–0.5 lg/ml and *32–128
lg/ml, and the difference among the six ﬂuoroquinolones
was marginal (Fig. 6).
Antimicrobial susceptibility of the Klebsiella
pneumoniae strains
Among the 35 antibacterial agents tested for K. pneumo-
niae, MEPM showed the highest activity with an MIC90 of
B0.06 lg/ml. A large number of antibiotics showed rela-
tively high antimicrobial activity against K. pneumoniae,
with MIC90s of 0.125–0.5 lg/ml, including two oral
cephalosporins (CCL and CDTR), ﬁve parenteral cepha-
losporins (CTM, CTRX, CAZ, CPR, and CFPM), one ox-
acephem (FMOX), four carbapenems (IPM, PAPM, BIPM,
DRPM), one monobactam (AZT), two aminoglycosides
(GM and ISP), and six ﬂuoroquinolones (CPFX, LVFX,
TFLX, GFLX, PUFX, and PZFX). The MIC90 of PIPC in
93 strains of K. pneumoniae was 64 lg/ml, whereas that
with TAZ was 4 lg/ml, which was 1/16 comparatively to
that without TAZ. None of the 93 K. pneumoniae strains
showed ESBL positivity (see Table 3).
Antimicrobial susceptibility of the Proteus mirabilis
strains
The MIC90 of two penicillins (ABPC and PIPC) against P.
mirabilis strains was C256 lg/ml; however, they were
decreased to 8 and 1 lg/ml, respectively, in combination
with b-lactamase inhibitors (SBT/ABPC and TAZ/PIPC)
(Fig. 7). Five strains of P. mirabilis (12%) of 42 were
found to be ESBL positive as tested by the Nitroceﬁn disks
and the Cica-Beta methods. The MIC90 of all cephalo-
sporins tested was 16 to C256 lg/ml, with the exception of
CAZ, of which the MIC90 was 0.25 lg/ml. The MIC
cumulative curves of cephalosporins revealed that the ratio
of the resistant strain according to the CLSI category was
about 10% (Figs. 8, 9). The carbapenem antibiotics showed
high antimicrobial activity against P. mirabilis with MIC90
of 0.25–4 lg/ml; however, the MIC cumulative curves
showed considerable variations among ﬁve carbapenems in
the following order: MEPM[DRPM[PAPM[ IPM =
BIPM (see Table 3; Fig. 10). The MIC90 of six ﬂuoro-
quinolones in P. mirabilis was 2 to C32 lg/ml, and the
ratio of the resistant strain was close to 20%. MINO
showed low antimicrobial activity against P. mirabilis with
85.7% of the strain resistant (see Table 3; Fig. 9).
Antimicrobial susceptibility of the Serratia marcescens
strains
The antibiotic susceptibility diagram of S. marcescens to
the 16 CLSI category antibacterial agents showed that the
ratio of the resistant strains of this organism to all antibi-
otics was less than 20%, except for CMZ (Fig. 11). The
MIC cumulative curves (Fig. 12) of 12 antibacterial agents
revealed that they could be roughly divided into three
groups. (1) The agents highly active against S. marcescens
were CAZ, CFPM, IPM, AZT, and CPFX. (2) The agents
moderately active were PIPC, TAZ/PIPC, CMZ, AMK,
MINO, and FOM. (3) The least active agent was CTM.
Neither the ESBL-producing strain nor the multidrug-
resistant strain was found in the S. marcescens tested in this
study.
Antimicrobial susceptibility of the Pseudomonas
aeruginosa strains
The MIC90 of the 25 antimicrobial agents in P. aeruginosa
was 4 to C256 lg/ml, except CL and PL-B, with MIC90 of
0.5 and 1.0 lg/ml, respectively. Three strains (2.6%) were
found to be metallo-b-lactamase positive, and two (1.8%)
were multidrug resistant (MDRP). The antibiotic suscep-
tibility diagram of P. aeruginosa to the 15 CLSI category
antibacterial agents (see Fig. 14) demonstrated that the
ratios of the resistant strains to PIPC, CAZ, CFPM, and
carbapenems were close to 10%, whereas those to ﬂuoro-
quinolones were between 35% and 40% (Figs. 13, 14). The
MIC cumulative curves in Fig. 13 showed that IPM and
CPFX were active against P. aeruginosa, PIPC, TAZ/
PIPC, CAZ, CFPM, AZT, and AMK were moderately
active, and MINO and FOM were less active than the
others. The MIC90 of the six ﬂuoroquinolones was
32–128 lg/ml, and the MIC cumulative curves showed a
broad distribution (Fig. 15).
Discussion
In community and hospital settings, the etiology of urinary
tract infections and the antimicrobial susceptibility of
130 J Infect Chemother (2011) 17:126–138
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Table 3 Antibacterial susceptibility of the major urinary pathogens
Enterococcus faecalis (N = 140) Escherichia coli (N = 255) Klebsiella pneumoniae (N = 93) Proteus mirabilis(N = 42) Serratia marcescens (N = 44) Pseudomonas aeruginosa (N = 114)
ESBL:13 ESBL:None ESBL:5 MDRP:2 MBL:3
Antibacterial agent MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90
Ampicillin 0.25–8 2 4 0.5–C256 8 C256 0.5–C256 2 C256
Amoxicillin/Clavlanate 0.25-C128 8 16 0.5-16 2 4 0.5-16 0.5 8
Ampicillin/Sulbactam 0.25-8 2 4 0.5-128 4 32 0.5-64 4 8 0.5-32 1 8
Piperacillin 0.5-16 4 4 0.25C256 2 C256 1-C256 4 64 0.125-C256 0.5 C256 0.5-128 4 64 1-C256 8 128
Piperacillin/
Tazobactam
0.5-16 4 4 0.25-64 2 4 0.5-16 2 4 0.125-64 0.25 1 0.5-128 2 128 0.5-C256 8 128
Cefaclor 0.125-C256 2 32 0.125-32 0.5 0.5 0.5-C256 1 C256
Cefditorene B0.06-C128 0.25 2 B0.06-4 0.25 0.5 B0.06-C128 B0.06 C128 0.25-C128 2 C128
Cefcapene B0.06-C256 0.5 2 B0.06-4 0.25 1 B0.06–64 B0.06 16 B0.06–C256 2 32
Cefazolin 0.5-C256 2 32 0.5-128 1 2 2-C256 4 C256
Cefmetazole 0.125-32 0.5 2 0.25-8 0.5 2 1-8 2 2 2-C256 8 128
Cefotiam B0.06-C256 0.25 2 B0.06-8 0.25 0.5 025–C256 0.25 C255 2–C256 C256 C256
Flomoxef B0.06-32 B0.06 0.25 B0.06-0.25 B0.06 0.125 0.125–0.5 0.25 0.25 0.25–C256 4 32
Ceftriaxone B0.06-256C B0.06 0.25 B0.06-8 B0.06 0.125 B0.06–C256 B0.06 32 B0.06–64 0.25 64 2–C256 64 C256
Ceftazidime B0.06-64 0.125 0.5 B0.06-0.5 0.125 0.25 B0.06–4 B0.06 0.25 B0.06–C128 0.25 4 0.5–C128 2 32
Cefpirome 0.5-C256 8 64 B0.06-C256 B0.06 0.125 B0.06-2 B0.06 0.125 B0.06–C256 B0.06 C256 B0.06–128 0.125 2 1–C256 8 64
Cefepime B0.06-128 B0.06 0.125 B0.06-1 B0.06 0.125 B0.06–C256 B0.06 128 B0.06–C256 0.125 4 0.5–C256 4 32
Imipenem 0.125-4 0.5 2 B0.06-0.5 0.125 0.25 B0.06-0.5 0.125 0.25 0.125–8 2 4 0.125–2 0.5 1 0.125–C128 1 8
Panipenem B0.06-8 1 2 B0.06-0.25 0.125 0.25 B0.06-0.25 0.125 0.25 0.125–4 2 4 0.125–8 0.25 1 0.25–C256 4 16
Meropenem 0.25-16 4 8 B0.06-0.25 B0.06 B0.06 B0.06 B0.06 B0.06 B0.06–0.5 B0.06 0.25 B0.06–2 B0.06 0.125 B0.06–C256 0.5 8
Biapenem 0.25-16 4 8 B0.06-1 B0.06 B0.06 B0.06-1 0.125 0.5 0.5–4 2 4 0.125–4 0.5 1 B0.06-C256 0.25 4
Doripenem 0.25-8 2 8 B0.06-0.125 B0.06 B0.06 B0.06-0.125 B0.06 0.125 B0.06–2 0.25 0.5 B0.06–2 0.125 0.25 B0.06–C128 0.25 8
Faropenem 0.25-16 1 4 0.125-4 0.5 1 0.25-2 0.25 1 0.25–4 1 2 0.5–128 8 64
Aztreonam B0.06-128 B0.06 0.5 B0.06-1 B0.06 0.125 B0.06–16 B0.06 0.125 B0.06–16 0.125 8 0.25–C256 4 32
Gentamicin 0.125-128 0.5 8 0.125-0.5 0.25 0.25 0.25–64 0.5 2 0.125–32 0.5 1 0.125–C256 2 4
Isepamicin 0.25-8 1 2 0.25-1 0.5 0.5 2-8 4 4 0.25–16 1 4 0.25–C256 4 8
Amikacin 0.5-16 2 4 0.5-2 1 2 1-8 4 4 0.5–64 2 16 0.25–128 4 8
Ciproﬂoxacin 0.25-128 1 32 B0.06-128 B0.06 32 B0.06-8 B0.06 0.25 B0.06-C256 B0.06 16 B0.06-C256 B0.06 16 B0.06-C256 0.25 64
Levoﬂoxacin 0.5-128 2 64 B0.06-128 0.125 16 B0.06-8 B0.06 0.5 B0.06-C256 0.125 8 B0.06-C256 0.125 16 B0.06-C256 1 128
Tosuﬂoxacin 0.125-C32 0.25 C32 B0.06-C32 B0.06 C32 B0.06-16 B0.06 0.25 B0.06-C32 0.125 C32 B0.06-C32 0.125 C32 B0.06-C32 0.5 C32
Gatiﬂoxacin 0.25-64 0.5 32 B0.06-128 0.125 16 B0.06-16 B0.06 0.5 0.125-C256 0.25 32 B0.06-C256 0.25 16 B0.06-C256 2 128
Pruliﬂoxacin 0.5-C64 1 C64 B0.06-C64 B0.06 8 B0.06-4 B0.06 0.25 B0.06-C64 B0.06 8 B0.06-C64 B0.06 8 B0.06-C64 0.25 32
Pazuﬂoxacin 1-C256 2 128 B0.06-64 B0.06 8 B0.06-4 B0.06 0.25 B0.06-C256 B0.06 2 B0.06-C256 0.125 8 B0.06-C256 0.5 64
Minocycline B0.06-32 8 16 0.125-C256 0.5 8 0.5-16 2 8 4-C256 16 32 0.5–32 4 8 4-C256 16 64
Fosfomicin 0.125-C256 0.5 4 0.5-C256 4 128 2-C256 8 C256 2-C256 64 C256
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urinary pathogens have been changing every year [7, 8].
Variables in the patient population and the extensive use
and misuse of antimicrobial agents could all contribute to
changes in the microbial proﬁle of urinary tract isolates [9].
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Fig. 3 Antimicrobial susceptibility of Escherichia coli was catego-
rized into three classes: susceptible, intermediate, or resistant,
according to the MIC breakpoints recommended by CLSI standards
M100-S18. Twenty-two antimicrobial agents were tested for the 255
strains of E. coli
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Fig. 1 Antimicrobial susceptibility of Enterococcus faecalis was
categorized into three classes: susceptible, intermediate, or resistant,
according to the minimum inhibitory concentration (MIC) break-
points recommended by Clinical and Laboratory Standards Institute
(CLSI) standards M100-S18. Seven antimicrobial agents were tested
for the 140 strains of E. faecalis
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Fig. 8 Cumulative MIC curves of cephems for P. mirabilis (number of
strains, 42).CCL, cefaclor;CDTR, cefditorene;CFPN, cefcapene;CEZ,
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Fig. 5 Cumulative (MIC) curves of cephems for E. coli (number of
strains, 255).CCL, cefaclor;CDTR, cefditorene;CFPN, cefcapene;CEZ,
cefazolin; CMZ, cefmetazole; CTM, cefotiam; FMOX, ﬂomoxef;CTRX,
ceftriaxone; CAZ, ceftazidime; CPR, cefpirome; CFPM, cefepime
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Fig. 9 Antimicrobial susceptibility of P. mirabilis was categorized
into three classes: susceptible, intermediate, or resistant, according to
the MIC breakpoints recommended by CLSI standards M100-S18.
Twenty-two antimicrobial agents were tested for the 42 strains of P.
mirabilis
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mirabilis (number of strains, 42). ABPC, ampicillin; CVA/AMPC,
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Fig. 4 Cumulative MIC curves of penicillin derivatives for E. coli
(number of strains, 255). ABPC, ampicillin; CVA/AMPC, amoxicillin/
clavlanate; SBT/ABPC, ampicillin/sulbactam; PIPC, piperacillin;
TAZ/PIPC, piperacillin/tazobactam
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Fig. 6 Cumulative MIC curves of ﬂuoroquinolones for E. coli
(number of strains, 255). CPFX, ciproﬂoxacin; LVFX, levoﬂoxacin;
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Striking evidence is seen in the increase of strains of E. coli
resistant to ﬂuoroquinolones, which could reﬂect the over-
use of quinolones for treatment of community-acquired
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Fig. 13 Cumulative MIC curves of antibacterial agents for Pseudo-
monas aeruginosa (number of strains, 114). PIPC, piperacillin; TAZ/
PIPC, piperacillin/tazobactam; CAZ, ceftazidime; CFPM, cefepime;
IPM, imipenem; AZT, aztreonam; AMK, amikacin; CPFX, ciproﬂox-
acin; MINO, minocycline; FOM, fosfomicin
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Fig. 14 Antimicrobial susceptibility of P. aeruginosa was catego-
rized into three classes: susceptible, intermediate, or resistant,
according to the MIC breakpoints recommended by CLSI standards
M100-S18. Fifteen antimicrobial agents were tested for the 114
strains of P. aeruginosa
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Fig. 15 Cumulative MIC curves of ﬂuoroquinolones for P. aerugin-
osa (number of strains, 114). CPFX, ciproﬂoxacin; LVFX, levoﬂox-
acin; TFLX, tosuﬂoxacin; GFLX, gatiﬂoxacin; PUFX, pruliﬂoxacin;
PZFX, pazuﬂoxacin
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Fig. 10 Cumulative MIC curves of carbapenems and penem for P.
mirabilis (number of strains, 42). IPM, imipenem; PAPM, panipenem;
MEPM, meropenem; BIPM, biapenem; DRPM, doripenem; FRPM,
faropenem
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Fig. 11 Antimicrobial susceptibility of Serratia marcescens was
categorized into three classes: susceptible, intermediate, or resistant,
according to the MIC breakpoints recommended by CLSI standards
M100-S18. Sixteen antimicrobial agents were tested for the 44 strains
of S. marcescens
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Fig. 12 Cumulative (MIC) curves of antibacterial agents for S.
marcescens (number of strains, 44). PIPC, piperacillin; TAZ/PIPC,
piperacillin/tazobactam; CMZ, cefmetazole; CTM, cefotiam; CAZ,
ceftazidime; CFPM, cefepime; IPM, imipenem; AZT, aztreonam;
AMK, amikacin; CPFX, ciproﬂoxacin; MINO, minocycline; FOM,
fosfomicin
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urinary tract infections. Some authors have advocated that
quinolone resistance is higher in developing countries than
in developed nations because of the use of less active
quinolones, such as nalidixic acid, and/or the use of inef-
fective doses with mutant isolates [10]. The use of short-
term treatment with quinolones for urinary tract infections,
which has been encouraged by some authors, could also
have contributed to mutant isolates [11]. On the other
hand, other authors have recommended that the use of
quinolones should be reduced, or at least rationed, and used
principally for urinary tract infections, to save this potent
class of antibiotics and avoid the development of resistance
among the Enterobacteriaceae [12]. An earlier study
reported that patient age, gender, and geographic location
had an impact on the incidence of antibiotic resistant
bacteria from urinary tract infections [13–17]. This study
revealed that the incidence of the CPFX-resistant strain
tended to be high in elderly patients (those less than
60 years of age compared to those 60 years of age or older:
25% vs. 33%) (data not shown). The high frequency of
ﬂuoroquinolone resistance in elderly individuals has been
reported previously [15, 16, 18]. In North America, it is
important that physicians are aware of regional resistance
ratios before initiating empirical antimicrobial therapy for
the treatment of urinary tract infections, as it is well doc-
umented that urinary tract infections with a resistant
pathogen are more likely to lead to bacteriological/clinical
failure [17, 19–21]. Additionally, in Japan no difference
was found between the resistance ratios in each hospital
(data not shown). It has also been reported that major risk
factors for ﬂuoroquinolone-resistant E. coli are recent
(within 4 weeks) ﬂuoroquinolone use and recurrent urinary
tract infections [18].
Some authors demonstrated that multi-genomic step
mutations were predominantly responsible for the emer-
gence of high-level resistance to ﬂuoroquinolones [22, 23].
For this reason, recognition of strains with low-level resis-
tance is important to avoid high-level resistant isolates and to
preserve the effectiveness of the newest ﬂuoroquinolones.
Enterococcus faecalis
Enterococcus faecalis showed high susceptibility to peni-
cillin derivatives compared to other antimicrobial agents
(see Fig. 1), notably to ABPC, of which the MIC in E. fae-
calis has been kept low for a long period of time [24–26]. In
fact, urinary tract infections of E. faecalis were empirically
treated with a combination of ABPC and aminoglycoside.
From the results of this observation, we assume that the
combination of b-lactam antibiotics and aminoglycoside
antibiotics could be used to treat urinary tract infections.
Another antibiotic found to be effective against E. faecalis
was vancomycin, with no strain resistant to VCM. This
ﬁnding is consistent with our earlier survey in 2002 [26], and
the results have not changed for the past 10 years.
The E. faecalis strains studied here showed marked
resistance to ﬂuoroquinolones with a resistance ratio of
35.7% (see Fig. 1). Our earlier study reported that the
percentage of ﬂuoroquinolone-resistant E. faecalis was
more than 40% in 1998 and, therefore, the ﬁgure has not
changed signiﬁcantly for the past 10 years [26]. Of great
concern would be that the 11 isolates of E. faecalis (7.8%)
were found to be linezolid intermediate resistant. Attention
needs to be focused on the trend of linezolid susceptibility
by E. faecalis.
Escherichia coli
For the current isolates of E. coli, the best susceptibility
score (100%) was achieved with carbapenems and AMK,
followed by TAZ/PIPC and CMZ with a score of 98.2%
and 97.9%, respectively. The combination of PIPC and
TAZ showed the MIC90 of 4 lg/ml, which was the lowest
value among the MIC90 of penicillin derivatives plus
b-lactamase inhibitor. For the antimicrobial prophylaxis in
the perioperative period of both open clean and clean-
contaminated urological surgeries, past guidelines recom-
mended preferential use of CEZ [27]. However, our data
did not support this earlier recommendation because the
MIC90 of CEZ in E. coli appeared to be 32 lg/ml. There-
fore, the earlier guideline [27] will be revised shortly.
The current isolate of E. coli showed a high resistance
ratio of 29.3% to ﬂuoroquinolones. As previously reported,
the susceptibility of E. coli to ﬂuoroquinolones is unstable
and, therefore, ﬂuoroquinolone-resistant strains emerge
rapidly [25]. The results of this study are consistent with
the earlier report and additionally found a considerable
number of ﬂuoroquinolone cross-resistant strains.
With the emergence of the quinolone antibiotic-resistant
E. coli, a few risk factors were noted: (a) the ﬂuoroquinolone
antibiotic treatment of community-acquired urinary tract
infections [18, 28, 29]; (b) the presence of underlying or
preexisting chronic disease(s) [17]; (c) patients with a uri-
nary tract abnormality; and (d) urinary catheter insertion
[29]. This study conﬁrmed that urinary catheterization was
one of the risk factors for ﬂuoroquinolone resistance (data
not shown). Previous reports have not cited hospitalization as
a risk factor for ﬂuoroquinolone-resistantE. coli urinary tract
infection; however, others have documented the increasing
ratios of E. coli resistance in an inpatient setting [30]. It is
plausible that patient-to-patient spread could provide an
explanation for these ﬁndings. Although inconsistent reports
were found in the literature, it is most likely that patient-to-
patient dissemination occurs in hospitals. With gender dif-
ferences, previous literature reported that ﬂuoroquinolone-
resistant E. coli strains were more frequently isolated from
J Infect Chemother (2011) 17:126–138 135
123
male patients with urinary tract infections as compared to
female patients [31]. This study conﬁrmed the same ten-
dency (data not shown).
Another problem is the emergence of multi-antibiotic-
resistant E. coli. Fluoroquinolone-resistant E. coli strains
isolated from patients with urinary tract infections were
frequently resistant to other antimicrobials. Development
of ﬂuoroquinolone-resistant E. coli is often associated with
mutations that lead to increased efﬂux of antimicrobial
agents such as an increased appearance of the AcrAB
multidrug efﬂux pump [32].
Another paper reported that the frequency of ESBL-
producing E. coli was twice as high in patients who had
ﬂuoroquinolone treatment (15% vs. 7.4%) [28]. This study
shows that 12 strains of 13 ESBL-producing E. coli were
cross-resistant to LVFX, suggesting a strong correlation
between the two mechanisms. However, it is not logical to
link the ﬂuoroquinolone resistance to ESBL production.
The only possibility is that the use of many different
classes of antibiotics in the same patient may cause the
mutants to be resistant to structurally and functionally
diverse antibiotics [33]. This study found 13 ESBL-pro-
ducing E. coli (5.1%), which is about ﬁve times higher than
that of our previous data, which showed only 4 ESBL-
producing E. coli (1.1%) among the 351 strains isolated in
2003 [25]. Thus, the frequency of ESBL-producing E. coli
from urinary tract infections is increasing, but as yet it is
not very high. Production of ESBL in E. coli largely con-
tributes to the resistance to the third- and fourth-generation
cephalosporins.
Other factors that may contribute to antibiotic resistance
would be the production of the plasmid-mediated ampC
b-lactamases and reduced outer membrane permeability
[34–36].
Klebsiella pneumoniae
This study showed that most K. pneumoniae isolated from
urinary tract infection patients were susceptible to antimi-
crobial agents tested so far. This result indicates that the
prevalence of antibiotic-resistant K. pneumoniae in Japan is
low compared to that in European and Latin American
countries where b-lactam-resistant K. pneumoniae was
reported to be abundant [37]. Only seven strains (7.5%) of
K. pneumoniae were resistant to PIPC (Fig. 16), and the
MIC90 was 64 lg/ml. The ESBL-producing K. pneumoniae
was not found in this study at all. However, another study
in Japan reported the presence of the ESBL-producing
K. pneumoniae [38] (see Fig. 16).
Proteus mirabilis
All the P. mirabilis strains, including ESBL-producing
strains, were susceptible to penicillin derivatives combined
with b-lactamase inhibitors (see Figs. 7, 9). Among the 42
strains tested, this study found 5 (11.9%) ESBL-producing
P. mirabilis. Among the 42 strains of P. mirabilis, 6 strains
(14.3%) were LVFX resistant (see Fig. 9), which is a slight
increase compared to the LVFX-resistant strains in an
earlier study that showed only 1 of 50 strains (2%) was
resistant [25]. Therefore, quinolone-resistant P. mirabilis is
not a great concern in Japan so far. However, the high
resistance rate of the pathogens to ﬂuoroquinolones
worldwide is of great concern because ﬂuoroquinolone
antibiotics are the most frequently used treatment.
Pseudomonas aeruginosa
Among P. aeruginosa isolates, this study revealed that the
ratio of resistant strains to penicillin, cephalosporin, and
carbapenem derivatives was close to 10%, except for
CTRX and AMK, which was less than 5%. In contrast,
ﬂuoroquinolone-resistant P. aeruginosa appeared to be
34.8%. Only 2 of 114 strains (1.8%) were found to be
MDRP. Infection of P. aeruginosa is empirically treated
with a combination of b-lactam and aminoglycoside, sug-
gesting that the emergence of aminoglycoside-resistant
P. aeruginosa can be expected to be low. In fact, AMK-
resistant P. aeruginosa appeared to be 4.4%.
Patients with urinary tract infections with underlying or
preexisting diseases could be divided into two categories: (1)
patients with a urinary catheter and (2) patients without a
catheter. In patients with a catheter, opportunistic pathogens
such as P. aeruginosa and S. marcescenswere often isolated
[24, 39, 40]. P. aeruginosa infections, often associated with
bioﬁlm formation [41], need to be aggressively treated.
Another problem with P. aeruginosa would be the
emergence and dissemination of MDRP. The MDR in
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Fig. 16 Antimicrobial susceptibility of Klebsiella pneumoniae was
categorized into three classes, namely, susceptible, intermediate, or
resistant, according to the MIC breakpoints recommended by CLSI
standards M100-S18. Twenty antimicrobial agents were tested for the
93 strains of K. pneumoniae
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P. aeruginosa is generally deﬁned as showing resistance to
IPM, AMK, and CPFX [39]. The incidence of MDRP seems
to be decreasing in the most recent 2 years compared to
1999–2001 [42]. We assume that this decreased incidence
of MDRP might be attributable to the well-planned use of
antimicrobial agents [25]. According to this study, con-
trolled and selective use of antibiotics could reduce the
emergence of antimicrobial-resistant bacteria. To do so, the
identiﬁcation of the urinary tract infection causative agent
through the use of a urine culture is essential.
Conclusion
The increasing prevalence of urinary tract infections and
antibiotic-resistant bacteria has made empirical antibiotic
treatment more and more difﬁcult. One of the important
issues causing the high frequency of antimicrobial-resis-
tant bacteria might be the aberrant use of antibiotics. A
urine culture and an antimicrobial susceptibility test of
the urine specimen seem to be essential for diagnosing
the disease, recommending the use of appropriate antibi-
otics, and reducing the number of antibiotic-resistant
uropathogens.
Periodic and long-term observation of urinary tract
infection pathogens and their antimicrobial susceptibility
provides essential information about the trends of antibiotic
resistance of these pathogens. The data obtained from this
study will help determine the optimal treatment for patients
with urinary tract infections and serve as a guide for con-
trolling antimicrobial-resistant pathogens.
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